Decellularized human heart valves
OtherDecellularized human aortic heart valves
Other names: Arise Aortic Valve (AV)
NCT Number: NCT02527629
Evaluation of decellularized human heart valves for aortic heart valve replacement in comparison to current valve substitutes.
Safety endpoints include cardiovascular adverse events, time to re-operation, re-intervention and explantation.
Efficacy endpoints include freedom from valve dysfunction and hemodynamic performance.
Looking for future studies?
Notify MeAll sexes
Observational
Universitair Ziekenhuis Leuven, UZL, Leuven, Belgium
This is a prospective, non-randomized, single-arm, multi-centre surveillance study to be conducted in Europe.
The Surveillance is designed as a study, where
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
i. Indication for aortic valve replacement according to current medical guidelines in valvular heart disease
ii. Informed consent of legal guardians or patients, assent of patients
Exclusion criteria
i. The patient has not provided Surveillance informed consent.
ii. The patient shall not suffer from:
iii. The coronary arteries of the patient shall not be in abnormal position or heavily calcified.
iv. Patients shall not show hypersensitivity against sodium dodecyl sulphate (SDS), sodium desoxycholate (SDC), human collagen (or other elastic fibers) or Benzonase®.
Decellularized human aortic heart valves
Other names: Arise Aortic Valve (AV)
Time frame: up to 24 months
Rate of cardiovascular AR, e.g. all-cause mortality, major stroke, life-threatening (or disabling) bleeding, acute kidney injury-stage 3 (including renal replacement therapy), peri-procedural myocardial infarction, major vascular complication, repeat procedure for valve-related dysfunction (surgical or interventional therapy).
Time frame: up to 24 months
Echocardiographic studies should be obtained and analyzed at discharge and at 3, 6 Months and at annual follow-ups. The requested variables include peak and mean systolic gradient, using pw and cw doppler, in the left ventricular outflow tract, respective the aortic valve. The echo evaluation (videotape or CD) should remain at the Surveillance site, but be available to corlife Surveillance personnel upon request. The MRIs will be analyzed by the MRI Core Laboratory at Medical School in Hannover for potential valvular stenosis, via phase contrast flow measurements in the aorta and for valvular competence, via phase contrast flow measurements and by ventricular volumetry. MRI cine images will be used to visualize the Surveillance valve in patients with poor echocardiographic windows.
Time frame: up to 24 months
The following data should be collected: Hb, LDH, Haptoglobin, CRP, Leukocytes. Blood studies should be performed within 7 days preoperatively and at discharge. Blood data will support the absence/presence of related AR. For example, haemolysis should be reported as an adverse event if anaemia is present; however, in the absence of anaemia, haemolysis will be considered to be compensated and does not require reporting. Time to events, such as death, reoperation including explantation will be evaluated for those outcomes, calculated from the date of operation.
Time frame: up to 24 months
Time to events, such as death, reoperation including explantation will be evaluated for those outcomes, calculated from the date of operation
Time frame: up to 24 months
Diameters of ARISE AV at end of the Surveillance will be analyzed in comparison to diameters at implantation and to age matched reference values. Preoperative non-invasive data on left ventricular size and function, such as left ventricular end diastolic, end systolic volume, ejection fraction and ventricular mass will be derived from MRI and compared to postoperative status.
corlife
Industry
Aortic Replacement Using Individualised Regenerative Allografts: Bridging the Therapeutic Gap - ARISE (the "Surveillance")
Acronym: ARISE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07626801
Cardiovascular Disease, Cardiovascular Diseases
Istanbul, Bakirköy, Turkey (Türkiye)
View Trial DetailsNCT06392464
Cardiovascular Diseases, Heart Diseases
Santiago de Compostela, Spain
View Trial DetailsNCT00291525
Cardiovascular Diseases, Heart Diseases
Tucson, Arizona, United States
View Trial DetailsNCT02035540
Cardiovascular Diseases, Heart Diseases
Leuven, Belgium
View Trial Details